Can Growth Hormone Reverse Ketobemidone-Induced Injury in Primary Cortical Neuronal Cell Cultures?
Independent thesis Advanced level (professional degree), 20 credits / 30 HE creditsStudent thesisAlternative title
Kan tillväxthormon förhindra skada i nervceller orsakade av opioider? (Swedish)
INTRODUCTION: Chronic exposure and abuse of opioids have been shown to reduce cognitive capabilities. Recent studies however indicate that growth hormone (GH) can have the ability to counteract these adverse effects, because of its neuroprotective properties. AIM: The aim of the present study was to examine the neurotoxic effects of ketobemidone and the neuroprotective effects of GH. MATERIALS AND METHODS: Primary cortical neurons, harvested from embryonic day 17 Sprague- Dawley rats, were fixed on 96-well plates and treated with ketobemidone for 24 hours to induce injury. Two types of assays, lactate dehydrogenase (LDH) and mitochondrial activity (MTT), were then used to calculate the lethal concentration. A neuroprotection study was subsequently executed by adding recombinant human GH (rhGH) to the neurons simultaneously as the optimal lethal concentration of ketobemidone. Finally, 10 μM naloxone was used on ketobemidone-treated cells to achieve opioid receptor blockade and examine whether cell damage occurs even when opioid receptors are blocked. RESULTS: The results showed that ketobemidone has neurotoxic effects in primary cortical neurons and that rhGH can counteract these adverse effects. Results also showed that some neurotoxicity occur even when opioid receptors are blocked. CONCLUSIONS: To summarize, treatment with GH may be a good way to prevent nerve cell damage caused by ketobemidone. However, the fact that neurotoxicity occurs even when opioid receptors are blocked suggests that other receptors than opioid receptors, such as NMDA-receptors, may be involved in the underlying mechanism.
Place, publisher, year, edition, pages
2016. , 33 p.
Pharmacology and Toxicology
IdentifiersURN: urn:nbn:se:uu:diva-297316OAI: oai:DiVA.org:uu-297316DiVA: diva2:941579
Subject / course
Master of Science Programme in Pharmacy
2016-06-01, Uppsala, 08:45 (English)
Hallberg, Mathias, Professor